Yes, one trial in the last 5 years. Which is why I said we’re nowhere close to knowing the long term effect of these dosage. The first SUSTAIN goes back to 2014 and we have about a decade of data. All the STEP trials are within 5 years.
You should also note that going from 1.0mg to 2.0mg (doubling the dosage) improved the HbA1c measure from 1.9% reduction to 2.1%. It’s statistically significant but the effect is also small (an improvement for treating severe patients but not so much for the rest of the disease population). Most of the reduction is in the body weight when increasing the dosage.
Right, but the weight loss increase was also very small
Mean change in bodyweight from baseline at week 40 was −6·9 kg with semaglutide 2·0 mg and −6·0 kg with semaglutide 1·0 mg
So glycated haemoglobin improves by 10 percent and weight loss increase by 15 percent.
This would suggest to me that whatever long term problems are associated with semaglutide at 2mg are probably going to be associated with semaglutide at 1mg at broadly similar rates.
Yes, one trial in the last 5 years. Which is why I said we’re nowhere close to knowing the long term effect of these dosage. The first SUSTAIN goes back to 2014 and we have about a decade of data. All the STEP trials are within 5 years.
You should also note that going from 1.0mg to 2.0mg (doubling the dosage) improved the HbA1c measure from 1.9% reduction to 2.1%. It’s statistically significant but the effect is also small (an improvement for treating severe patients but not so much for the rest of the disease population). Most of the reduction is in the body weight when increasing the dosage.
Right, but the weight loss increase was also very small
So glycated haemoglobin improves by 10 percent and weight loss increase by 15 percent.
This would suggest to me that whatever long term problems are associated with semaglutide at 2mg are probably going to be associated with semaglutide at 1mg at broadly similar rates.
Time will tell though!